Drug-coated balloons for the treatment of coronary artery lesions combined with diabetes mellitus
-
摘要: 糖尿病是冠状动脉(冠脉)疾病和心血管事件的主要危险因素，其患者复杂的血管情况也是经皮冠脉介入治疗(PCI)所面临的主要挑战之一。尽管药物洗脱支架的使用降低了糖尿病患者的冠脉再狭窄率，但与非糖尿病患者相比，糖尿病患者支架置入术后发生主要不良心血管事件的风险仍然增加。为了进一步降低支架术后并发症，在无植入理念的驱动下，药物涂层球囊(DCB)作为冠脉介入治疗新手段应运而生，为合并糖尿病的冠脉病变介入治疗提供了新策略。本综述总结了近年来DCB用于治疗糖尿病患者冠脉病变的临床研究，以探究DCB治疗冠脉血管病变合并糖尿病的疗效和安全性。
-
关键词:
- 糖尿病 /
- 冠心病 /
- 药物涂层球囊 /
- 经皮冠状动脉介入治疗
Abstract: Diabetes mellitus is a major risk factor for coronary artery disease and cardiovascular events, and the complex vascular profile of its patients is one of the major challenges facing PCI. Although the use of drug-eluting stents has reduced the rate of coronary restenosis in diabetic patients, there is still an increased risk of MACE after stent placement in diabetic patients compared to non-diabetic patients. To further minimize post-stenting complications, drug-coated balloon(DCB) has emerged as a new means of coronary intervention driven by the no-implantation concept, which provides a new strategy for interventional treatment of coronary lesions with comorbid diabetes. This review summarizes the clinical studies on the use of DCB for the treatment of coronary artery lesions in diabetic patients in recent years, in order to investigate the efficacy and safety of DCB for the treatment of coronary artery vasculopathy combined with diabetes mellitus. -
-
[1] Zhao D, Liu J, Wang M, et al. Epidemiology of cardiovascular disease in China: current features and implications[J]. Nat Rev Cardiol, 2019, 16(4): 203-212. doi: 10.1038/s41569-018-0119-4
[2] Goodarzi MO, Rotter JI. Genetics insights in the relationship between type 2 diabetes and coronary heart disease[J]. Circ Res, 2020, 126(11): 1526-1548. doi: 10.1161/CIRCRESAHA.119.316065
[3] Minacapelli A, Piraino D, Buccheri D, et al. Drug-coated balloons for the treatment of in-stent restenosis in diabetic patients: A review of currently available scientific data[J]. Catheter Cardiovasc Interve, 2018, 92(1): E20-E27.
[4] Sugiyama T, Yamamoto E, Bryniarski K, et al. Coronary plaque characteristics in patients with diabetes mellitus who presented with acute coronary syndromes[J]. J Am Heart Associ, 2018, 7(14): e009245. doi: 10.1161/JAHA.118.009245
[5] Yahagi K, Kolodgie FD, Lutter C, et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus[J]. Arter Thromb Vasc Biol, 2017, 37(2): 191-204. doi: 10.1161/ATVBAHA.116.306256
[6] Nasu K, Tsuchikane E, Katoh O, et al. Plaque characterisation by Virtual Histology intravascular ultrasound analysis in patients with type 2 diabetes[J]. Coronary Artery Disease, 2022, 12: 110.
[7] Kereiakes DJ, Young JJ. Percutaneous coronary revascularization of diabetic patients in the era of drug-eluting stents[J]. Rev Cardiovasc Med, 2005, 6 Suppl 1: S48-58.
[8] Wilson S, Mone P, Kansakar U, et al. Diabetes and restenosis[J]. Cardiovasc Diabetol, 2022, 21(1): 23. doi: 10.1186/s12933-022-01460-5
[9] Outcomes in diabetics undergoing revascularization: the long and the short of it-PubMed[EB/OL]. [2024-01-16].
[10] Koskinas KC, Siontis GCM, Piccolo R, et al. Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity: patient-level pooled analysis of 6081 patients[J]. Cardiovasc Int, 2016, 9(2): e003255.
[11] Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus-PubMed[EB/OL]. [2024-01-16].
https://pubmed.ncbi.nlm.nih.gov/11056089/ .[12] Smith SC, Faxon D, Cascio W, et al. Prevention Conference Ⅵ: Diabetes and Cardiovascular Disease: Writing Group Ⅵ: revascularization in diabetic patients[J]. Circulation, 2002, 105(18): e165-169.
[13] Fan CH, Tsai CY, Lai CY, et al. Feasibility of in vitro calcification plaque disruption using ultrasound-induced microbubble inertial cavitation[J]. Ultrasonics, 2024, 138: 107238. doi: 10.1016/j.ultras.2023.107238
[14] Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators[J]. New Engl J Med, 1994, 331(8): 496-501. doi: 10.1056/NEJM199408253310802
[15] Daemen J, Garcia-Garcia HM, Kukreja N, et al. The long-term value of sirolimus-and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus[J]. Eur Heart J, 2007, 28(1): 26-32.
[16] Biondi-Zoccai GGL, Agostoni P, Abbate A, et al. Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a meta analysis of randomized bare-metal-stent-controlled trials[J]. Int J Cardiol, 2005, 100(1): 119-123. doi: 10.1016/j.ijcard.2004.11.001
[17] Iijima R, Ndrepepa G, Mehilli J, et al. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era[J]. Am Heart J, 2007, 154(4): 688-693. doi: 10.1016/j.ahj.2007.06.005
[18] Arslani K, Jeger R. Drug-coated balloons for small coronary disease-a literature review[J]. Curr Cardiol Rep, 2021, 23(11): 173. doi: 10.1007/s11886-021-01586-0
[19] Chang M, Park DW. Optimal duration of dual antiplatelet therapy after implantation of drug-eluting stents: shorter or longer?[J]. Cardiol Ther, 2014, 3(1-2): 1-12. doi: 10.1007/s40119-014-0030-y
[20] 孙楷文, 王虹艳. 药物涂层球囊在冠脉病变中的应用[J]. 大连医科大学学报, 2022, 44(3): 255-262, 268.
[21] 陈韵岱, 邱春光, 唐强, 等. 药物涂层球囊临床应用中国专家共识(第二版)[J]. 中国介入心脏病学杂志, 2023, 31(6): 413-426. doi: 10.3969/j.issn.1004-8812.2023.06.003
[22] Jeger RV, Eccleshall S, Wan Ahmad WA, et al. Drug-coated balloons for coronary artery disease: third report of the international DCB consensus group[J]. JACC Cardiovasc Int, 2020, 13(12): 1391-1402. doi: 10.1016/j.jcin.2020.02.043
[23] Biondi-Zoccai G, Moretti C, Abbate A, et al. Percutaneous coronary intervention for small vessel coronary artery disease[J]. Cardiovasc Revasc Med, 2010, 11(3): 189-198. doi: 10.1016/j.carrev.2009.04.007
[24] Benjamin BK, Lu W, Han Z, et al. Drug-coated balloon-only angioplasty outcomes in diabetic and nondiabetic patients with de novo small coronary vessels disease[J]. J Int Cardiol, 2021, 2021: 2632343.
[25] 马骏, 黄亚敏. 药物球囊在糖尿病患者冠脉介入治疗中的特点及效果分析[J]. 中国实用医药, 2021, 16(5): 11-14.
[26] 郭淑丽, 孙晓花. 药物涂层球囊在对糖尿病合并冠状动脉小血管病变患者进行PCI治疗中的应用效果[J]. 当代医药论丛, 2021, 19(3): 63-64. doi: 10.3969/j.issn.2095-7629.2021.03.043
[27] Yu X, Ji F, Xu F, et al. Treatment of large de novo coronary lesions with paclitaxel-coated balloon only: results from a Chinese institute[J]. Clin Res Cardiol, 2019, 108(3): 234-243. doi: 10.1007/s00392-018-1346-8
[28] Pan L, Lu W, Han Z, et al. Clinical outcomes of drug-coated balloon in coronary patients with and without diabetes mellitus: a multicenter, propensity score study[J]. J Diabetes Res, 2021, 2021: 5495219.
[29] Pi SH, Rhee TM, Lee JM, et al. Outcomes in patients with diabetes mellitus according to insulin treatment after percutaneous coronary intervention in the second-generation drug-eluting stent era[J]. Am J Cardiol, 2018, 121(12): 1505-1511. doi: 10.1016/j.amjcard.2018.02.034
[30] Ann SH, Balbir Singh G, Lim KH, et al. Anatomical and physiological changes after paclitaxel-coated balloon for atherosclerotic de novo coronary lesions: serial IVUS-VH and FFR Study[J]. PLoS One, 2016, 11(1): e0147057. doi: 10.1371/journal.pone.0147057
[31] Jun EJ, Shin ES, Teoh EV, et al. Clinical outcomes of drug-coated balloon treatment after successful revascularization of de novo chronic total occlusions[J]. Front Cardiovasc Med, 2022, 9: 821380. doi: 10.3389/fcvm.2022.821380
[32] Megaly M, Ali A, Abraham B, et al. Outcomes with drug-coated balloons in percutaneous coronary intervention in diabetic patients[J]. Cardiovasc Revasc Med, 2020, 21(1): 78-85. doi: 10.1016/j.carrev.2019.03.001
[33] Giannini F, Latib A, Jabbour RJ, et al. Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients-results from the BELLO(balloon elution and late loss optimization)trial[J]. Cardiovasc Revasc Med, 2017, 18(1): 4-9. doi: 10.1016/j.carrev.2016.12.008
[34] Mieres J, Fernandez-Pereira C, Risau G, et al. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry(DEAR)[J]. Cardiovasc Revasc Med, 2012, 13(5): 265-271. doi: 10.1016/j.carrev.2012.06.001
[35] 周明锴, 刘小军, 张丹丹, 等. 药物洗脱球囊与药物洗脱支架治疗合并糖尿病冠状动脉小血管病变的疗效对比[J]. 心肺血管病杂志, 2020, 39(12): 1420-1423. doi: 10.3969/j.issn.1007-5062.2020.12.002
[36] Wöhrle J, Scheller B, Seeger J, et al. Impact of diabetes on outcome with drug-coated balloons versus drug-eluting stents the BASKET-SMALL 2 Trial[J]. JACC Cardiovasc Int, 2021, 14(16): 1789-1798. doi: 10.1016/j.jcin.2021.06.025
[37] 王雪娜, 张佩生, 梁雪, 等. 药物涂层球囊治疗糖尿病患者冠状动脉大血管原位病变的疗效与安全性分析[J]. 临床心血管病杂志, 2022, 38(3): 181-185. https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2022.03.004
[38] Rosenberg M, Waliszewski M, Krackhardt F, et al. Drug coated balloon-only strategy in de novo lesions of large coronary vessels[J]. Int Cardiol, 2019, 2019: 6548696. .
[39] Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter[J]. N Engl J Med, 2006, 355(20): 2113-2124. doi: 10.1056/NEJMoa061254
[40] Claessen BE, Henriques JPS, Vendrik J, et al. Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial[J]. Catheter Cardiovasc Int, 2019, 93(2): 216-221. doi: 10.1002/ccd.27814
[41] Lee JM, Park J, Kang J, et al. Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials[J]. JACC Cardiovasc Int, 2015, 8(3): 382-394.
[42] Buccheri D, Piraino D, Andolina G, et al. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment[J]. J Thoracic Dis, 2016, 8(10): E1150-E1162. doi: 10.21037/jtd.2016.10.93
[43] Sedlis SP, Morrison DA, Lorin JD, et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry[J]. J Am Coll Cardiol, 2002, 40(9): 1555-1566. doi: 10.1016/S0735-1097(02)02346-X
[44] Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2022, 145(3): e18-e114.
[45] Shin ES, Jun EJ, Kim S, et al. Clinical impact of drug-coated balloon-based percutaneous coronary intervention in patients with multivessel coronary artery disease[J]. JACC Cardiovasc Int, 2023, 16(3): 292-299. doi: 10.1016/j.jcin.2022.10.049
[46] Her AY, Shin ES, Kim S, et al. Drug-coated balloon-based versus drug-eluting stent-only revascularization in patients with diabetes and multivessel coronary artery disease[J]. Cardiovasc Diabetol, 2023, 22(1): 120. doi: 10.1186/s12933-023-01853-0
[47] 夏屿鸥, 宋耀明. 糖尿病患者合并冠脉分叉病变药物洗脱球囊扩张术疗效观察[J]. 第三军医大学学报, 2018, 40(24): 2260-2265.
[48] 李锦爽, 王万虹, 周浩, 等. 药物洗脱球囊治疗糖尿病伴复杂冠状动脉病变的临床效果[J]. 介入放射学杂志, 2019, 28(8): 770-772. doi: 10.3969/j.issn.1008-794X.2019.08.014
-
计量
- 文章访问数: 462
- PDF下载数: 90
- 施引文献: 0
下载: